Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 18/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 18/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 18/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 16/20 | 0.52 |
| ▸ | TSHR | P16473 | 14/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 11/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 8/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 7/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29970935 | 0.88 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL23283349 | 0.88 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL29805343 | 0.84 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL23273972 | 0.84 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL15904872 | 0.83 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL29772253 | 0.81 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL31301703 | 0.80 | STK4 (0.60) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL30642226 | 0.80 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL24399767 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR | |
| SCHEMBL30402020 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C19CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220372040-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| CN-115279756-A | METTL3 modulators | 埃克森特治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4048670-A1 | METTL3 MODULATORS | Accent Therapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021081211-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081211-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| EP-3191489-B1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-01-06 | — | — | EP | disclosed |
| US-9932346-B2 | Pyrrolopyrimidines for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-03 | — | — | US | disclosed |
| US-9932346-B2 | Pyrrolopyrimidines for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-03 | — | — | US | disclosed |
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-07 | — | — | US | disclosed |
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372040-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | CYP1A2 1036/4885CYP3A4 426/4885CYP2C19 1902/4885 |
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | IMPDH1, IMPDH2, TYMP | CYP1A2 45/4885CYP3A4 89/4885CYP2C19 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.